MRD
Showing 26 - 50 of 1,776
MRD Recurrence Monitoring After Surgical Resection of
Not yet recruiting
- HCC
- Liver resection
- (no location specified)
Jul 10, 2022
Clinical Performance Evaluation of the C2i Test
Not yet recruiting
- Muscle Invasive Bladder Cancer
- C2i-WGS-MRD Test
- (no location specified)
May 5, 2023
Using Mass Spectrometry Detecting Minimal Residual Disease in
Recruiting
- Multiple Myeloma
-
Tianjin, ChinaInsituteHBDH
Sep 8, 2022
s Recurrence and Response Via a Tumor Informed Assessment
Recruiting
- Cancer
- +4 more
- Personalized Cancer Monitoring (PCM)
-
San Francisco, California
- +1 more
Dec 5, 2022
Colorectal Cancer Trial in Shanghai, Hangzhou, Ningbo (Capecitabine tablets, Oxaliplatin)
Not yet recruiting
- Colorectal Cancer
- Capecitabine tablets
- Oxaliplatin
-
Shanghai, Shanghai, China
- +3 more
Jan 16, 2023
Multiple Myeloma Trial (Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT
Not yet recruiting
- Multiple Myeloma
- Dara-VRd intensification, Dara-R maintenance
- +4 more
- (no location specified)
Dec 13, 2022
Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab
Not yet recruiting
- Ph+ ALL
- +2 more
- the usage of Olverembatinib combined with Inotuzumab Ozogamicin
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital, Chinese Acade
Oct 30, 2022
MRD Application in Colorectal Cancer Patients
Recruiting
- Colorectal Cancer
- +2 more
-
Jinan, Shandong, ChinaJinan central hospital affiliated to Shandong First Medical Univ
Sep 1, 2023
Significance of MRD After Surgery in Driver Gene-positive and
Enrolling by invitation
- NSCLC MRD ctDNA
-
Shenzhen, ChinaShenzhenPH
Jun 30, 2022
Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))
Recruiting
- Mixed Phenotype Acute Leukemia (MPAL)
- Measurable Residual Disease (MRD)
- BLINCYTO (Blinatumomab)
-
Baltimore, MarylandGreenebaum Cancer Center at University of Maryland Medical Cente
Apr 18, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Pirtobrutinib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
-
Houston, TexasM D Anderson Cancer Center
Nov 17, 2022
Parkinson Disease Trial in Ann Arbor (Multifunctional RehabilitationDevice (MRD), existing standard rehabilitation device)
Recruiting
- Parkinson Disease
- Multifunctional RehabilitationDevice (MRD)
- existing standard rehabilitation device
-
Ann Arbor, MichiganThe University of Michigan
Dec 8, 2022
Cancer Trial in New Orleans, Allentown
Recruiting
- Cancer
-
New Orleans, Louisiana
- +1 more
Oct 14, 2022
Bone Marrow Failure Syndromes Trial in Philadelphia (MRD-BMT with Fludarabine-based RIC for Acquired AA, MRD-BMT with
Recruiting
- Bone Marrow Failure Syndromes
- MRD-BMT with Fludarabine-based RIC for Acquired AA
- +2 more
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
May 6, 2022
Local Advanced Esophageal Carcinoma
Recruiting
- Esophageal Squamous Cell Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai cancer center
Jun 16, 2022
Multiple Myeloma, Cancer, Hematologic Cancer Trial in Cork (Discontinuation of maintenance treatment)
Not yet recruiting
- Multiple Myeloma
- +2 more
- Discontinuation of maintenance treatment
-
Cork, IrelandCork University Hospital
May 10, 2023
Acute Myeloid Leukemia, Measurable Disease Trial in Tianjin (Venetoclax, Azacitidine, Venetoclax, daunorubicin, cytarabine)
Recruiting
- Acute Myeloid Leukemia
- Measurable Disease
- Venetoclax, Azacitidine
- Venetoclax, daunorubicin, cytarabine
-
Tianjin, Tianjin, ChinaHBDH
Apr 28, 2022
B-ALL Trial in Hangzhou (ThisCART19A)
Recruiting
- B-ALL
- ThisCART19A
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Apr 26, 2022
MRD Monitoring in Lung Cancer After Resection
Recruiting
- Lung Cancer
- MRD detection
-
Guangzhou, Guangdong, ChinaGuangdong Lung Cancer Institute & Guangdong Provincial People's
Mar 2, 2022
First-Line Serplulimab Plus Chemotherapy in Treatment of
Not yet recruiting
- Lung Cancer
- Serplulimab plus chemotherapy
- (no location specified)
May 16, 2023
MRD Trial in China (Adjuvant treatment for MRD positivity)
Recruiting
- MRD
- Adjuvant treatment for MRD positivity
-
Beijing, China
- +15 more
Sep 12, 2022
Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia Trial in Aurora (CD19 Directed CAR T Cell)
Not yet recruiting
- Acute Lymphoid Leukemia
- Acute Lymphoblastic Leukemia
- CD19 Directed CAR T Cell
-
Aurora, ColoradoUniversity of Colorado Hospital
Sep 12, 2022